| Name | Diphenmanil methylsulfate |
| Description | Diphenmanil methylsulfate (Diphemanil mesylate), a quaternary ammonium anticholinergic, binds muscarinic acetylcholine receptors and thus decreases secretory excretion of stomach acids, sweat, and saliva. |
| In vitro | Pharmacokinetic studies indicate that Diphemanil Methylsulphate is slowly absorbed, with a peak time (tmax) of 2-4 hours and an average half-life of 8.35 hours. Within 48 hours, 0.6%-7.4% of the administered dose is recovered in the urine. The compound exhibits poor gastrointestinal absorption, with bioavailability ranging from 15% to 25%. |
| In vivo | Diphemanil Methylsulfate exerts its anticholinergic effects primarily by binding to muscarinic M3 receptors, and it also acts directly on smooth muscle to provide antispasmodic benefits. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 50 mg/mL (128.37 mM), Sonication is recommended.
H2O : 26 mg/mL (66.8 mM)
Ethanol : < 1 mg/mL (insoluble or slightly soluble)
|
| Keywords | Diphemanil | Diphemanil Mesylate | Muscarinic acetylcholine receptor | Diphenmanil | Inhibitor | mAChR | Diphenmanil methylsulfate | inhibit |
| Inhibitors Related | Adiphenine hydrochloride | Nanofin | Arecoline hydrobromide | Forskolin | CLOZAPINE N-OXIDE | Pilocarpine nitrate | Ribavirin | Adenine | Choline chloride | Propoxur |
| Related Compound Libraries | Bioactive Compound Library | Anti-Neurodegenerative Disease Compound Library | Neuronal Signaling Compound Library | Anti-Alzheimer's Disease Compound Library | Membrane Protein-targeted Compound Library | Neurotransmitter Receptor Compound Library | Drug Repurposing Compound Library | NO PAINS Compound Library | FDA-Approved Drug Library | Bioactive Compounds Library Max |
United States
